ESC 365 - Welcome and introduction - Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension.

ESC Premium Access

Welcome and introduction - Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension.

Session: Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension

Topic: CHF - Non pharmacological treatment

Speaker: Professor S. Anker (Berlin, DE) Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Organised by Charité Medical School, supported with an educational grant by CVRx

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speakers

Professor Stefan Anker

Charite University Hospital, Berlin (Germany)

171 presentations

11 followers

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

103 presentations

4 followers

3 more presentations in this session

Why is the baroreflex a relevant target for both resistant hypertension and heart failure?

Speaker: Professor A. Pathak (Monaco, MC)

Resistant hypertension: stimulating the baroreflex when drugs have failed.

Speaker: Professor P. De Leeuw (Maastricht, NL)

Heart failure with reduced ejection fraction and a narrow QRS: how can baroreflex activation therapy help?

Speaker: Professor C. Butter (Bernau bei Berlin, DE)

Access the full session

Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension

Speakers: Professor S. Anker, Professor F. Zannad, Professor A. Pathak, Professor P. De Leeuw, Professor C. Butter

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources